Inhibikase Therapeutics (Inhibikase Therapeutics) EBITDA Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Inhibikase Therapeutics's EBITDA for the three months ended in Mar. 2024 was $-4.78 Mil. Inhibikase Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Inhibikase Therapeutics's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.

Inhibikase Therapeutics EBITDA Margin % Historical Data

The historical data trend for Inhibikase Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibikase Therapeutics EBITDA Margin % Chart

Inhibikase Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

Inhibikase Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Inhibikase Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Inhibikase Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's EBITDA Margin % falls into.

Inhibikase Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Inhibikase Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-19.912	/	0
	=	%

Inhibikase Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-4.776	/	0
	=	%

Inhibikase Therapeutics (NAS:IKT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Inhibikase Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339

Website

https://www.inhibikase.com

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Executives

Paul C Grint	director	7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman	director	9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman	director	256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner	director, 10 percent owner, officer: President and CEO	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli	officer: Cheif Financial Officer
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman	10 percent owner	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339